Furthermore, in public databases, the expression of PD1 and CTLA4 was utilized to predict patient response to ICI treatment; thus, HCC patients treated with ICIs were required to evaluate the true predictive usefulness of HM13. Here, CTLA4 is linked to hepatocellular carcinoma.